White Paper: 7 Steps for Allogeneic Cell Therapy Success
![](https://breakthroughmedicines.com/wp-content/uploads/2023/02/CBM_Endpoints_417_v3.jpg)
Center for Breakthrough Medicines
In the new white paper, CBM experts, explore the latest strategies and technologies for allogeneic cell therapy success.
Allogeneic, or “donor-derived”, CAR T cells have the potential to broaden access to treatment for patients. To prepare for commercial scale, companies must think through a number of considerations around scale-up, aseptic processing, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.
Allogeneic, or “donor-derived”, CAR T cells have the potential to broaden access to treatment for patients. To prepare for commercial scale, companies must think through a number of considerations around scale-up, aseptic processing, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.
In need of immediate assistance for your product development? Simply call to speak with a CBM expert: 866-274-4009.